Hofseth Biocare ASA: FOURTH QUARTER 2021 FINANCIAL REPORT
04 févr. 2022 01h59 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA (“HBC”) had gross operating revenues of NOK 26.1m (23.1m) in the fourth quarter and total operating revenues of NOK 87.6m (69.3) for the full year. Cost of sales (CoGS) amounted to...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
22 déc. 2021 08h34 HE
|
Hofseth Biocare ASA
Roger Hofseth has today, 22 December 2021, bought 50,000 shares at an average price of approx. NOK 7.332 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the...
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
03 déc. 2021 07h55 HE
|
Hofseth Biocare ASA
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Friday 3 December 2021. The proposal for supplementary election of Amy...
Hofseth Biocare ASA: HBC INGREDIENTS SUCCESSFULLY RECEIVE NEW DIETARY INGREDIENT (NDI) STATUS FROM THE US FDA
02 déc. 2021 02h45 HE
|
Hofseth Biocare ASA
Hofseth Biocare ASA is Now Part of an Exclusive Short-List of Companies to Have Successfully Obtained NDI Status for CalGo® and OmeGo® Nutritional Supplements Extracted from Norwegian Atlantic salmon....
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
18 nov. 2021 08h40 HE
|
Hofseth Biocare ASA
Roger Hofseth has today, 18 November 2021, bought 55,000 shares at an average price of approx. NOK 7.25 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the...
Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
08 nov. 2021 11h41 HE
|
Hofseth Biocare ASA
An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company’s premises in Kipervikgata 13, 6003 Ålesund on 3 December 2021 at 13:00 CET, for supplementary election to the Board...
Hofseth Biocare ASA: NEW POTENTIAL PHARMACEUTICAL DRUG LEADS BY HBC
05 nov. 2021 03h06 HE
|
Hofseth Biocare ASA
As noted in the CEO Statement in our Q3 Financial Report issued today, 5 November 2021, Hofseth BioCare ASA (“HBC”) is a consumer and pet health ingredient supplier and an incubator for new drug...
Hofseth Biocare ASA: THIRD QUARTER 2021 FINANCIAL REPORT
05 nov. 2021 03h05 HE
|
Hofseth Biocare ASA
HBC had net sales revenues of NOK 13.7m (7.6m) in the third quarter and total operational revenues of NOK 61.5m (46.2) for the first nine months. Cost of Goods Sold (CoGS) amounted to NOK 13.6m (7.6m)...
Hofseth Biocare ASA: THE BOARD OF DIRECTORS PROPOSES TO ELECT AMY NOVOGRATZ AS NEW DIRECTOR
04 nov. 2021 14h32 HE
|
Hofseth Biocare ASA
Reference is made to the stock exchange notice dated 4 November 2021 on global investment fund Aqua Spark's off-market acquisition of a 3.38 % stake in Hofseth Biocare ASA ("HBC"). In a board...
Hofseth Biocare ASA: AQUA SPARK AS NEW STRATEGIC INVESTOR IN HBC
04 nov. 2021 11h12 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA ("HBC") has been informed that Aqua Spark has acquired 12,100,000 shares in an off-market transaction with Bonafide at a price per share of NOK 8.10. Aqua Spark's purchase...